Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia

Cancer

Volumn 115, Issue 6, 2009, Pages 1169-1173

  Pedrazzoli, Paolo ^a   Rosti, Giovanni ^b   Secondino, Simona ^a   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Radiological Department   (Italy)

Author keywords

Cancer anemia; Chemotherapy; Erythropoiesis stimulatory agents; Iron supplementation

Indexed keywords

ANTINEOPLASTIC AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BREAST TUMOR; CANCER THERAPY; COLORECTAL TUMOR; DRUG EFFICACY; FEMALE GENITAL TRACT TUMOR; FERRITIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON THERAPY; LUNG TUMOR; LYMPHATIC SYSTEM TUMOR; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANEMIA; ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; FERRIC COMPOUNDS; HEMATINICS; HUMANS; NEOPLASMS;

EID: 63449089728     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24115     Document Type: Review

References (23)

1. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89:4248-4267.
2. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002;87: 1209-1221.
3. Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ. 1992;304:225-226.
4. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:1416-1423.
5. Katodritou E, Terpos E, Zervas K, et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol. 2007;86:369-376.
6. Fishbane S, Frei GL, Mesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41-46.
7. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-1699.
8. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;1:530-538.
9. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369:1502-1504.
10. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-382.
11. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26:132-149.
12. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627-632.
13. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open label, randomized trial. J Clin Oncol. 2004;22:1301-1307.
14. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231-242.
15. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med. 2007;356:2445-2448.
16. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113:1251-1253.
17. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20: 4083-4107.
18. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy- induced anemia. J Clin Oncol. 2008;25:1611-1618.
19. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol. 2008;25:1619-1625.
20. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2007;94:1211-1220.
21. Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol. 2008;25:1579-1581.
22. Beguin Y. Erythropoietic agents and iron. In: Bokemeyer C, Ludwig H, eds. Anaemia in Cancer. ESO Scientific Updates. Vol 6. 2nd ed. Edinburgh, Scotland: Elsevier; 2005:199-220.
23. Auerbach M, Ballard H. Intravenous iron in oncology. J Natl Compr Canc Netw. 2008;6:585-592.